secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALIMERA SCIENCES INC (—)
CIK:        0001267602
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0001267602-23-000050
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 3.02, 3.03, 5.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alimera acquires U.S. rights to YUTIQ from EyePoint for $75M; projects $100M revenue in 2024
--------------------------------------------------------------------------------

- Upfront payment of $75M plus $7.5M guaranteed quarterly payments in 2024; royalties from 2025 at mid-to-low double digits on US net sales above thresholds starting $70M.
- Concurrent $69M equity raise via Series B Preferred and common stock; $20M additional term loan from SLR.
- Alimera projects at least $100M consolidated net revenue and >$20M Adjusted EBITDA in 2024.
- Board changes: Dr. Garheng Kong resigned; Jason Werner (Velan designee) appointed to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267602/000126760223000050/0001267602-23-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267602/000126760223000050/alim-20230516x8k.htm
  HTML page:      https://secwatch.observer/filing/0001267602-23-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer